Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04747145 · ClinicalTrials.gov registry record · Phase 2
Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04747145 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 38 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04747145, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary protocol objective is to assess the impact of substituting pulsed reduced dose radiotherapy (pRDR) for standard radiation therapy in the upfront treatment of glioblastoma (GBM) on disease progression.
Conditions Studied
Interventions
- DEVICE Radiation
- DRUG Concurrent Chemotherapy (Temozolomide)
- DRUG Adjuvant Chemotherapy (Temozolomide)
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-06-03 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04747145
The ClinicalTrials.gov registry entry for NCT04747145 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (65% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Radiation is the first listed.
NCT04747145 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04747145 about?
NCT04747145 is a clinical study titled "Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma". The primary protocol objective is to assess the impact of substituting pulsed reduced dose radiotherapy (pRDR) for standard radiation therapy in the upfront treatment of glioblastoma (GBM) on disease progression.
What is the current status of trial NCT04747145?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2021-06-03. Estimated completion is 2027-09.
What conditions does trial NCT04747145 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04747145?
The interventions under investigation include: Radiation (DEVICE), Concurrent Chemotherapy (Temozolomide) (DRUG), Adjuvant Chemotherapy (Temozolomide) (DRUG).
Who is sponsoring clinical trial NCT04747145?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04747145 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.